Press the l key to open the language menu.
Skip Main Navigation and go to Content

The implant includes an antenna, an electronics case, and an electrode array.

Status US Launch

The Argus® II Retinal Prosthesis System ("Argus II") will be initially offered in 12 major markets across the U.S. to treat patients with late stage retinitis pigmentosa (RP). This news follows U.S. market approval for the Argus II by the Food and Drug Administration (FDA) in February 14, 2013. The Argus II is the first and only "bionic eye" to be approved in countries throughout the world, including the U.S.

Current and future implant centers are located at nationally recognized and prestigious hospitals in:

Ann Arbor, MI

Dallas, TX

Nashville, TN

Atlanta, GA

Durham, NC

Philadelphia, PA

Baltimore, MD

Los Angeles, CA

San Francisco, CA

Chicago, IL

Miami, FL

 

Cleveland, OH

   

In order to make the Argus II therapy more widely accessible to patients with end-stage RP, the company will continue to actively identify additional centers across the country, while at the same time working to ensure adequate insurance coverage for the system and the medical activities surrounding the delivery of the therapy. Second Sight encourages interested patients and surgical centers to contact the company for more information.

For further information about our product in the US or to be put on a notification list please call Second Sight Customer Service toll free at (855) 756-3703 we are located in Sylmar, California (Pacific time zone).

If you are an ophthalmologist that is interested in learning more about becoming an Argus II center please call Brian Mech, VP Business Development (818)- 833-5026